Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

Wenjing Wu, Yaping Yang, Haizhu Chen, Yongkui Lu, Yinduo Zeng, Jianli Zhao, Caiwen Du, Ying Lin, Peijian Peng, Mei Huang, Ying Zhang, Quchang Ouyang, Linxiaoxiao Ding, Ziliang Cheng, Yuanyu Wen, Zhiyong Wu, Jinhui Ye, Li Ling, Kun Wang, Ying Lu, Guorong Zou, Jincai Zhong, Hong Wang, Daren Lin, De Ze · 2026

Read Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial by Wenjing Wu, Yaping Yang, Haizhu Chen, Yongkui Lu, Yinduo Zeng, Jianli Zhao, Caiwen Du, Ying Lin, Peijian Peng, Mei Huang, Ying Zhang, Quchang Ouyang, Linxiaoxiao Ding, Ziliang Cheng, Yuanyu Wen, Zhiyong Wu, Jinhui Ye, Li Ling, Kun Wang, Ying Lu, Guorong Zou, Jincai Zhong, Hong Wang, Daren Lin, De Ze (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13194736.txt.

Description

Wenjing Wu and a large team run the FAMILY trial, a phase 3 test of hormone therapy as upkeep care in spread breast cancer. The patients had hormone-sensitive, HER2-negative tumors that first answered chemotherapy. Upkeep care aims to hold that gain. Their 2026 trial spans 22 hospitals in mainland China. In all, 210 patients were split evenly between fulvestrant shots and capecitabine pills.

The hormone arm held the cancer back far longer. Median time without growth ran near twice the pill arm's span. Severe side effects were also rarer on the hormone arm. Survival data were not yet ripe at the cutoff. The team backs fulvestrant as the stronger upkeep pick after a good first response.

Catalog record

CREATORWenjing Wu, Yaping Yang, Haizhu Chen, Yongkui Lu, Yinduo Zeng, Jianli Zhao, Caiwen Du, Ying Lin, Peijian Peng, Mei Huang, Ying Zhang, Quchang Ouyang, Linxiaoxiao Ding, Ziliang Cheng, Yuanyu Wen, Zhiyong Wu, Jinhui Ye, Li Ling, Kun Wang, Ying Lu, Guorong Zou, Jincai Zhong, Hong Wang, Daren Lin, De Ze
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13194736

Browse the full library · About the Tower of Babel